Moderna reports real-world mNEXSPIKE effectiveness data in older adults
Moderna said on November 11, 2026 that JAMA Network Open published a Veterans Health Administration study comparing mNEXSPIKE with Comirnaty in adults aged 65 years and older. Among 294,499 matched U.S. veterans, mNEXSPIKE was associated with 35.9% relative effectiveness against medically attended COVID-19 and 47.0% against COVID-19-related hospitalization. An exploratory analysis found 39.3% relative effectiveness against hospitalization involving a major adverse cardiovascular event.
Why it matters
The publication gives Moderna comparative real-world evidence for mNEXSPIKE in an older population, which could support its positioning against Comirnaty. The study was observational, and its reported associations do not establish causality or necessarily generalize beyond the predominantly older, male Veterans Health Administration population.
Key facts
- 1The analysis covered 294,499 matched participants from the U.S. Veterans Health Administration. investingnews.com
- 2Compared with Comirnaty, mNEXSPIKE showed 35.9% relative vaccine effectiveness against medically attended COVID-19, with a 95% CI of 20.4%-49.7%. investingnews.com
- 3mNEXSPIKE showed 47.0% relative vaccine effectiveness against COVID-19-associated hospitalization, with a 95% CI of 5.4%-74.8%. investingnews.com
- 4The exploratory MACE hospitalization analysis reported 39.3% relative vaccine effectiveness, with a 95% CI of 11.8%-57.0%. investingnews.com
- 5The cohort included veterans vaccinated from August 27, 2025, through January 31, 2026, and follow-up lasted up to 150 days or through May 1, 2026. investingnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.